Eli Lilly and Company (LLY)
$1113.73-1.16%
Spriggl Score: Good— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“GLP-1 franchise leader with clinical superiority and deep pipeline; tirzepatide concentration is the key risk.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, H…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $905.8B
Recent dividends
- 15 May 2026$1.73
- 13 Feb 2026$1.73
- 14 Nov 2025$1.50
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Eli Lilly and Company and 1,600+ UK and US stocks.
Start free